


Investor Relations Brief

1

2025

January



Business Division Progress Report

Molecular Diagnostics and Bio Division

The Molecular Diagnostics and Bio Division has obtained export approval from the Ministry of Food and Drug Safety (MFDS) for the IRON-qPCR™ CRE Kit (Carbapenem-Resistant Gene Detection Kit). Carbapenem is a crucial antibiotic used to treat various bacterial infections. However, if resistance to this antibiotic occurs, resistant bacteria can rapidly spread, posing a critical threat, especially to patients in intensive care units or those with weakened immune systems. This product enables fast analysis within 40 minutes from sample input to results, which is expected to play an essential role in early response and infection control within medical institutions.

In addition, additional funding for the development of the IRON-qPCR™ RFIA Kit for Tuberculosis and Broad-Spectrum Drug Resistance Diagnosis aimed at acquiring WHO-PQ certification has been finalized through the support of the RIGHT Foundation. This additional support was granted in recognition of the achievements of the original project contracted in 2019. As a result, the initial 3.2 billion KRW project has been expanded to a total of 8.7 billion KRW by the end of 2026. Through this, continuous collaboration with FIND (a WHO-affiliated global nonprofit organization that leads diagnostic development and supply) will be maintained to conduct multinational clinical trials for tuberculosis and drug resistance. Plans are in place to apply for WHO-PQ certification.

CosmeRNA

CosmeRNA gained significant attention on December 5th by being featured in a special article jointly produced by ITN Business and the British Skin Foundation in the UK. The article promoted the CosmeRNA Intensive and its associated 4-month hair care program, which includes biweekly in-clinic treatments and at-home care routines.

Subsequently, on December 8th, at the Korean Laser Skin & Hair Association meeting, the product received positive feedback as an innovative and effective hair loss solution based on unique and groundbreaking technology. In particular, during a corporate seminar showcasing case results from real-world use on both men and women at a clinic in the UAE, the product received enthusiastic responses from dermatologists, hair loss specialists, and other industry experts.

AceBiome

AceBiome is accelerating its efforts to expand into the Chinese market by entering the Tmall Global platform, a premium e-commerce marketplace in China. Additionally, thanks to its focus on expanding domestic and international sales this year, the company was honored with the "700 Million Dollar Export Tower" award at the 61st Trade Day ceremony. This is a meaningful achievement following its "300 Million Dollar Export Tower" award in 2021, and the company plans to further concentrate on expanding sales channels and strengthening global revenue next year.

In celebration of the year-end, AceBiome successfully concluded its "Slim Donation" campaign in collaboration with the Goodwill Store of the Miral Welfare Foundation. Held for the third consecutive year, this campaign promotes the idea of achieving lightness in both body and mind by encouraging people to declutter their wardrobes and participate in sharing. It goes beyond simple donations to advocate for healthy living and sustainable values. AceBiome plans to continue spreading the meaning of such charitable activities while fulfilling its social responsibilities.

siRNAgen

siRNAgen Therapeutics is systematically working on preparations for the Phase 1b clinical trial and submitting the Phase 1a trial results for publication. Stability testing for the drug substance (DS) used in the follow-up clinical trial is underway at the contract manufacturing organization (CMO) responsible for DS production, with analysis for the 3-month stability test scheduled to begin in January next year. Drug product (DP) production will be carried out by a separate CMO, and the final institution has been selected after evaluating domestic and international GMP-certified facilities. To apply for the Investigational New Drug (IND) approval for the Phase 1b clinical trial, the company is preparing the Common Technical Document (CTD), which includes analytical data on the DS to be used for manufacturing clinical trial materials, production process information, and results from Phase 1a trials.

Additionally, regarding the submission of the Phase 1a trial results for publication, siRNAgen is finalizing additional analysis items and plans to complete the analysis by January next year through an external CRO to ensure objectivity and reliability of the results.

'CosmeRNA' Gains Attention at the Korean Laser Skin & Hair Association

On December 8th, Bioneer participated in the Korean Laser Skin & Hair Association and successfully showcased CosmeRNA, a hair loss cosmetic applied to the scalp, which is currently being sold in Europe. CosmeRNA has attracted significant attention from medical professionals in the field of hair loss management, thanks to its differentiated technology and safety.



Dr. Youngjin Park of Gangnam Samsung Plastic Surgery Clinic presented case results of actual use on male and female patients conducted at a clinic in the UAE, drawing significant attention. Additionally, the CosmeRNA booth attracted a large number of visitors and received high acclaim.

